PHARMOBEDIENT
GenericsPHARMOBEDIENT is a generic drug manufacturer focused on Cardiovascular, Infectious Disease, Neurology. Key products include LAMIVUDINE AND ZIDOVUDINE.
PHARMOBEDIENT's Key Drugs
PHARMOBEDIENT's core commercial portfolio centers on LYPQOZET, ALLZITAL, NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, spanning Cardiovascular and Infectious Disease — its most strategically important drugs approved in the last 15 years.
Myocardial Infarction
Headache
Osteoarthritis
Allergic Rhinitis
Hypertriglyceridemia
PHARMOBEDIENT's Recent FDA Approvals
PHARMOBEDIENT secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
PHARMOBEDIENT's Therapeutic Areas
PHARMOBEDIENT's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Infectious Disease, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PHARMOBEDIENT's Top Competitors
PHARMOBEDIENT's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PHARMOBEDIENT Pipeline Snapshot
Active clinical trials for PHARMOBEDIENT across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LYPQOZET leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (7)
Discontinued (7)
Company Info
- First Approval
- 1939-06-05
- Latest
- 2026-06-18
- Applications
- 306